1202P Final analysis of TENEC trial: A phase II trial of temozolomide (TMZ) as second-line treatment for advanced neuroendocrine carcinomas (NEC) in patients (pts) with a poor performance status (PS)
| Autor: | von Arx, C., Cannella, L., Marretta, A.L., Bracigliano, A., Tatangelo, F., Clemente, O., Iervolino, D., Granata, V., Mocerino, C., Modica, R., Pizzolorusso, A., Bianco, A., Picozzi, F., Di Sarno, A., Tafuto, S. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S708-S709 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|